What does Cosentyx (secukinumab) do, and how might that affect a COVID infection?
Cosentyx is an immune-modulating biologic (it blocks IL-17A). Because it changes parts of the immune response, people taking it ask whether they are more likely to catch COVID, develop severe disease, or have different symptom courses. The most practical guidance in the real world is usually symptom- and severity-based: clinicians consider whether to continue or temporarily hold an immunomodulator during an active infection, balancing flare risk against infection-control concerns.
Should you keep taking Cosentyx if you test positive for COVID?
For many immune-modulating therapies, clinicians commonly follow a “pause during active infection” approach when symptoms are significant, but the exact recommendation depends on:
- whether you have mild symptoms vs. pneumonia/hypoxia
- your risk factors for severe COVID (age, lung disease, diabetes, immunocompromise, etc.)
- how long it has been since your last dose and when the next dose is due
- your underlying condition (for example, psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis), and how likely you are to flare if treatment is delayed
If you share your condition, your dosing schedule, and how you’re feeling (mild cold symptoms vs. shortness of breath, fever, oxygen levels), I can help you think through the typical decision points to discuss with your prescriber.
Is it riskier to get severe COVID while on IL-17 blockers?
People on biologics are usually advised to be cautious, especially if they have other risk factors. The key point for IL-17 inhibitors like Cosentyx is that they are immunomodulatory rather than broad chemotherapy-level immunosuppression, so the practical risk assessment tends to be individualized. Your clinician may also consider whether you should qualify for early antiviral treatment if you’re at higher risk.
Can you take COVID antivirals (like Paxlovid) if you’re on Cosentyx?
In most cases, COVID antivirals are considered based on drug-drug interactions and kidney/liver function, not on biologic exposure itself. Cosentyx is a monoclonal antibody and is not typically associated with the same interaction patterns as small-molecule antivirals. Still, the safe answer depends on the specific antiviral, your other medications, and your lab results—so prescriber/pharmacist confirmation is important.
What happens to psoriasis or arthritis if Cosentyx is paused during COVID?
Delaying Cosentyx can increase the chance of a flare of psoriasis and related joint/axial symptoms. That’s why clinicians often weigh two competing risks:
- risk of worsening infection if immunomodulation continues
- risk of disease flare if treatment is held
Many treatment plans use a short, temporary hold during the acute phase and then resume when symptoms improve, but the timing is individualized.
When is it safer to resume Cosentyx after COVID?
Resuming usually focuses on clinical recovery (improving symptoms and resolution of fever) rather than a single test date, but the exact “when to restart” varies by severity of illness and local guidance. Severe COVID (hospitalization, oxygen needs) typically leads to a longer, more cautious restart plan.
What should patients watch for during COVID while on Cosentyx?
People on biologics should take COVID warning signs seriously and seek urgent care if they develop:
- trouble breathing or worsening shortness of breath
- chest pain/pressure
- persistent high fever or rapidly worsening symptoms
- confusion, severe weakness, or dehydration
- low oxygen readings if you’re monitoring at home
Where can I find drug-specific and policy-related information?
DrugPatentWatch tracks patents and exclusivity details for branded products like Cosentyx, and it’s sometimes useful for understanding the broader commercial landscape of competitors and biosimilars, which can affect access. You can explore Cosentyx-related entries here: DrugPatentWatch - Cosentyx.
---
If you want a more precise answer
Tell me:
1) Are you currently taking Cosentyx for psoriasis, psoriatic arthritis, or ankylosing spondylitis?
2) What was your last injection date and when is your next dose due?
3) How severe is your COVID (mild symptoms at home vs. shortness of breath/hospital care)?
4) Any major risk factors (age, lung disease, diabetes, other immunosuppressants)?
With that, I can map the most relevant “continue vs hold vs restart” considerations you’d typically discuss with your clinician.